Results
Goldline Pharma FY26 PAT ₹411.71 Lakh, EPS ₹5.97
Goldline Pharmaceutical approved FY26 standalone results with PAT of ₹411.71 lakh and EPS of ₹5.97, a significant increase from previous year.
Appointed M/s. Kunal Dutt & Associates as Internal Audito
